Novel non-nucleoside HCV NS5B inhibitors exhibit low potential for CYP-mediated drug-drug interactions

被引：0
|
作者：
Sergeeva, Maria [1 ]
LeBrun, Laurie A. [1 ]
Hou, Huiying [1 ]
Kirkovsky, Leo [1 ]
Zhou, Yuefen [1 ]
机构：
[1] Anadys Pharmaceut Inc, San Diego, CA USA
来源：
FASEB JOURNAL | 2009年 / 23卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
749.6
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Quantitative Structure-Activity Relationship Study of the Non-Nucleoside Inhibitors of HCV NS5B Polymerase by Machine Learning Methods
    Cong Yong
    Xue Ying
    ACTA PHYSICO-CHIMICA SINICA, 2013, 29 (08) : 1639 - U392
  • [22] Selection and characterization of hepatitis C virus replicons using combination of NS3 protease and NS5B non-nucleoside inhibitors or combination of NS5B nucleotide inhibitors
    Lam, A. M.
    Bonsal, S.
    Espiritu, C.
    Otto, M. J.
    Furman, P. A.
    ANTIVIRAL THERAPY, 2010, 15 : A28 - A28
  • [23] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE POTENTIAL CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDI) WITH SELUMETINIB.
    Zhou, L.
    Cohen-Rabbie, S.
    Vishwanathan, K.
    Schalkwijk, S.
    Tomkinson, H.
    Al-Huniti, N.
    Zhou, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S92 - S93
  • [24] GSK2878175, A POTENT NON-NUCLEOSIDE INHIBITOR OF HCV NS5B WITH PAN-GENOTYPIC ACTIVITY
    Hamatake, R.
    Voitenleitner, C.
    Crosby, R.
    Walker, J.
    Wang, A.
    Wright, L.
    Shotwell, B.
    Leivers, M.
    Peat, A.
    Hong, Z.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S496 - S496
  • [25] Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase
    Sofia, Michael J.
    Chang, Wonsuk
    Furman, Phillip A.
    Mosley, Ralph T.
    Ross, Bruce S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (06) : 2481 - 2531
  • [26] A non-nucleoside inhibitor of BVDV replication targeted to a novel noncatalytic region within NS5b polymerase
    LaFemina, R
    Wolanski, B
    Fay, JF
    Graham, DJ
    Ludmerer, SW
    McMasters, DR
    Carroll, SS
    Tomassini, J
    Flores, OA
    ANTIVIRAL THERAPY, 2002, 7 (04) : L102 - L102
  • [27] Multi-step parallel synthesis enabled optimization of benzofuran derivatives as pan-genotypic non-nucleoside inhibitors of HCV NS5B
    Xiao, Dong
    Dai, Xing
    Liu, Hong
    He, Shuwen
    Shi, Zhi-Cai
    Ludmerer, Steven W.
    Li, Fangbiao
    Nargund, Ravi
    Palani, Anandan
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (07)
  • [28] Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase:: discovery and preliminary SAR of benzimidazole derivatives
    Beaulieu, PL
    Bös, M
    Bousquet, Y
    Fazal, G
    Gauthier, J
    Gillard, J
    Goulet, S
    LaPlante, S
    Poupart, MA
    Lefebvre, S
    McKercher, G
    Pellerin, C
    Austel, V
    Kukolj, G
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) : 119 - 124
  • [29] Predictive factors of clinically significant drug-drug interactions among regimens based on protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir
    Cervero, Miguel
    Torres, Rafael
    Jose Jusdado, Juan
    Pastor, Susana
    Luis Agud, Jose
    MEDICINA CLINICA, 2016, 146 (08): : 339 - 345
  • [30] Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors
    Das, Debasis
    Hong, Jian
    Chen, Shu-Hui
    Wang, Guangyi
    Beigelman, Leonid
    Seiwert, Scott D.
    Buckman, Brad O.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (16) : 4690 - 4703
12345